Cargando…
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
Autores principales: | Talamonti, M., Tofani, L., Bianchi, L., Galluzzo, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344026/ https://www.ncbi.nlm.nih.gov/pubmed/32647977 http://dx.doi.org/10.1007/s00403-020-02103-z |
Ejemplares similares
-
Cardiovascular risk factors in psoriatic disease: psoriasis
versus psoriatic arthritis
por: Barbarroja, Nuria, et al.
Publicado: (2019) -
Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
por: Galluzzo, Marco, et al.
Publicado: (2020) -
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
por: Galluzzo, Marco, et al.
Publicado: (2022) -
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
por: Campione, Elena, et al.
Publicado: (2023) -
Symptomless Pulmonary Cryptococcosis in a Psoriatic Arthritis Patient during Infliximab Therapy
por: Yamada, Saori, et al.
Publicado: (2016)